B of A Securities raises Taysha price target to $10
B of A Securities analyst Tazeen Ahmad maintained a Buy rating on Taysha Gene Therapies and raised the price target to $10 from $9.

*this image is generated using AI for illustrative purposes only.
B of A Securities analyst Tazeen Ahmad has maintained a Buy rating on Taysha Gene Therapies. The firm raised the price target to $10 from $9.
Rating and Target Details
The revised price target reflects an increased valuation outlook for the company. The previous target was $9.
| Metric | Value |
|---|---|
| Rating | Buy |
| New Price Target | $10 |
| Previous Price Target | $9 |
What specific factors drove the increased valuation outlook for Taysha Gene Therapies?
How might this rating change influence investor sentiment in the biotech sector?
What upcoming clinical milestones could further impact the stock's performance?

























